These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3781425)

  • 21. Isolation of a novel metabolizing system enriched in phase-II enzymes for short-term genotoxicity bioassays.
    Paolini M; Pozzetti L; Silingardi P; Della Croce C; Bronzetti G; Cantelli-Forti G
    Mutat Res; 1998 Mar; 413(3):205-17. PubMed ID: 9651530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vinylidene chloride: changes in drug-metabolizing enzymes, mutagenicity and relation to its targets for carcinogenesis.
    Oesch F; Protić-Sabljić M; Friedberg T; Klimisch HJ; Glatt HR
    Carcinogenesis; 1983 Aug; 4(8):1031-8. PubMed ID: 6347425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of metabolism of chemicals with respect to carcinogenicity tests.
    Butschak G; Teichmann B; Scheunig G
    Pol J Pharmacol Pharm; 1979; 31(6):667-73. PubMed ID: 121597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and cellular basis for adequate metabolic design of genotoxicity studies.
    Oesch F; Oesch-Bartlomowicz B; Arens HJ; Friedberg T; Utesch D; Glatt HR; Platt KL
    Toxicol Lett; 1992 Dec; 64-65 Spec No():643-9. PubMed ID: 1335182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methodologies for the determination of various genetic effects in permeable strains of E. coli K-12 differing in DNA repair capacity. Quantification of DNA adduct formation, experiments with organ homogenates and hepatocytes, and animal-mediated assays.
    Mohn GR; Kerklaan PR; van Zeeland AA; Ellenberger J; Baan RA; Lohman PH; Pons FW
    Mutat Res; 1984 Feb; 125(2):153-84. PubMed ID: 6230533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of short-term mutagenicity test systems in vitro: metabolic activation of indirectly acting mutagens by three immortal rat hepatocyte lines.
    Kulka U; Paul D; Bauchinger M
    Mutagenesis; 1993 May; 8(3):193-7. PubMed ID: 8332081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xenobiotic metabolism and toxicity in primary monolayer cultures of hepatocytes.
    Holme JA
    NIPH Ann; 1985 Dec; 8(2):49-63. PubMed ID: 3908998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Species differences in activating and inactivating enzymes related to in vitro mutagenicity mediated by tissue preparations from these species.
    Oesch F
    Arch Toxicol Suppl; 1980; 3():179-94. PubMed ID: 6994685
    [No Abstract]   [Full Text] [Related]  

  • 29. Greater effectiveness of hepatocyte and liver S9 preparations from hamsters than rat preparations in activating N-nitroso compounds to metabolites mutagenic to Salmonella.
    Raineri R; Poiley JA; Andrews AW; Pienta RJ; Lijinsky W
    J Natl Cancer Inst; 1981 Nov; 67(5):1117-22. PubMed ID: 6946249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term assays to predict carcinogenicity. Metabolic activation.
    Venitt S; Bartsch H; Becking G; Fuchs RP; Hofnung M; Malaveille C; Matsushima T; Mendelsohn ML; Pegg AE; Roberfroid M
    IARC Sci Publ; 1986; (83):439-55. PubMed ID: 3305349
    [No Abstract]   [Full Text] [Related]  

  • 31. Detoxification of genotoxic compounds as a threshold mechanism limiting their carcinogenicity.
    De Flora S
    Toxicol Pathol; 1984; 12(4):337-43. PubMed ID: 6442795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary studies on the ability of Drosophila microsomal preparations to activate mutagens and carcinogens.
    Baars AJ; Blijleven WG; Mohn GR; Natarajan AT; Breimer DD
    Mutat Res; 1980 Sep; 72(2):257-64. PubMed ID: 6777691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutagenicity of five arylamines after metabolic activation with isolated dog and human hepatocytes.
    Neis JM; Yap SH; Van Gemert PJ; Roelofs HM; Henderson PT
    Cancer Lett; 1985 May; 27(1):53-60. PubMed ID: 4005824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinogen-metabolizing enzymes and susceptibility to chemical carcinogenesis.
    Bartsch H; Aitio A; Camus AM; Malaveille C; Roberfroid M; Vo Thi KO; Sabadie N
    IARC Sci Publ; 1983; (51):147-56. PubMed ID: 6321342
    [No Abstract]   [Full Text] [Related]  

  • 35. Incorporation of mammalian metabolism into mutagenicity testing.
    Malling HV
    Mutat Res; 2004 May; 566(3):183-9. PubMed ID: 15082236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of the correlation of bacterial mutagenicity with carcinogenicity of benzo(a)pyrene and four of its major metabolites by activation with intact liver cells instead of cell homogenate.
    Glatt HR; Billings R; Platt KL; Oesch F
    Cancer Res; 1981 Jan; 41(1):270-7. PubMed ID: 7448766
    [No Abstract]   [Full Text] [Related]  

  • 37. Species specificity in the metabolism of N-nitrosobis(2-oxopropyl)amine and N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine to mutagens by isolated rat and hamster hepatocytes.
    Mangino MM; Hollenberg PF; Scarpelli DG
    Cancer Res; 1987 Sep; 47(18):4776-81. PubMed ID: 3113724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic activation of drugs in mutagenicity tests in vitro.
    Roberfroid MB
    Arch Toxicol; 1980 Nov; 46(1-2):181-93. PubMed ID: 7235994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro metabolic activation in genotoxicity assays with mammalian cell cultures.
    Belvedere G
    Boll Chim Farm; 1985 Feb; 124(2):57-68. PubMed ID: 4015867
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolic activation of dimethylnitrosamine to mutagens: role of cytochromes P-450 and P-448.
    Phillipson CE; Ioannides C; Parke DV
    Toxicol Lett; 1982 Apr; 11(1-2):95-101. PubMed ID: 7046142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.